CN111920897A - 一种防治新型冠状病毒肺炎的中药组合物及其饮品的制备方法 - Google Patents
一种防治新型冠状病毒肺炎的中药组合物及其饮品的制备方法 Download PDFInfo
- Publication number
- CN111920897A CN111920897A CN202010395720.8A CN202010395720A CN111920897A CN 111920897 A CN111920897 A CN 111920897A CN 202010395720 A CN202010395720 A CN 202010395720A CN 111920897 A CN111920897 A CN 111920897A
- Authority
- CN
- China
- Prior art keywords
- parts
- filtrate
- traditional chinese
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 239000003814 drug Substances 0.000 title claims abstract description 46
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 30
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000000706 filtrate Substances 0.000 claims abstract description 32
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 16
- 241000951473 Schizonepeta Species 0.000 claims abstract description 16
- 244000068988 Glycine max Species 0.000 claims abstract description 15
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 15
- 235000006533 astragalus Nutrition 0.000 claims abstract description 15
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 14
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract description 14
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract description 14
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract description 14
- 210000003038 endothelium Anatomy 0.000 claims abstract description 14
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 14
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 13
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 13
- 235000011477 liquorice Nutrition 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 244000124853 Perilla frutescens Species 0.000 claims abstract description 5
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 3
- 235000004348 Perilla frutescens Nutrition 0.000 claims abstract description 3
- 238000009835 boiling Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 15
- 241001061264 Astragalus Species 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 210000004233 talus Anatomy 0.000 claims description 12
- 235000004347 Perilla Nutrition 0.000 claims description 9
- 235000013361 beverage Nutrition 0.000 claims description 8
- 238000002791 soaking Methods 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 25
- 208000024891 symptom Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 210000004072 lung Anatomy 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 206010037660 Pyrexia Diseases 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 241000229722 Perilla <angiosperm> Species 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 210000001835 viscera Anatomy 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- 208000025721 COVID-19 Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 208000006083 Hypokinesia Diseases 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000001174 ascending effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 208000017574 dry cough Diseases 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- -1 microelements Chemical class 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000008855 peristalsis Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002633 protecting effect Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000004202 respiratory function Effects 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 241000906579 Actaea cimicifuga Species 0.000 description 2
- 241000202726 Bupleurum Species 0.000 description 2
- 241001678559 COVID-19 virus Species 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 241000756943 Codonopsis Species 0.000 description 2
- 206010013789 Dry throat Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- 206010035148 Plague Diseases 0.000 description 2
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical group O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002542 deteriorative effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 208000018875 hypoxemia Diseases 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 2
- 229960002194 oseltamivir phosphate Drugs 0.000 description 2
- 230000008557 oxygen metabolism Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- QLPRYZXNWYTFCI-UHFFFAOYSA-N saikosaponin D Natural products CC1OC(OC2CCC3(C)C(CCC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C2(C)CO)C(O)C(O)C1OC8OC(CO)C(O)C(O)C8O QLPRYZXNWYTFCI-UHFFFAOYSA-N 0.000 description 2
- PQPVAGWUNWFCJE-UHFFFAOYSA-N saikosaponin a Natural products CC1OC(OC2CCC3(C)C(C2)C(C)(CO)CC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C(O)C(OC8OC(CO)C(O)C(O)C8O)C1O PQPVAGWUNWFCJE-UHFFFAOYSA-N 0.000 description 2
- GLQYFMRUYWFXGT-UHFFFAOYSA-N saikosaponin b3 Natural products C1CC2(C)C3C(OC)C=C4C5CC(C)(C)CCC5(CO)C(O)CC4(C)C3(C)CCC2C(C)(CO)C1OC(C1O)OC(C)C(O)C1OC1OC(CO)C(O)C(O)C1O GLQYFMRUYWFXGT-UHFFFAOYSA-N 0.000 description 2
- GNVUHIXVRODVRA-UHFFFAOYSA-N saikosaponin-b2 Natural products CC1OC(OC2CCC3(C)C(CCC4(C)C3C=CC5=C6CC(C)(C)CCC6(CO)C(O)CC45C)C2(C)CO)C(O)C(O)C1OC7OC(CO)C(O)C(O)C7O GNVUHIXVRODVRA-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- GLQYFMRUYWFXGT-ZGFARVGISA-N (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,4R,4aR,6aR,6bS,8S,8aS,12aS,14R,14aR,14bS)-8-hydroxy-4,8a-bis(hydroxymethyl)-14-methoxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-6-methyloxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O([C@H]1[C@@H](O)[C@@H](C)O[C@H]([C@@H]1O)O[C@@H]1[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)C[C@H](O)[C@@]5(CO)CCC(C)(C)C[C@H]5C4=C[C@H]([C@@H]3[C@@]2(C)CC1)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GLQYFMRUYWFXGT-ZGFARVGISA-N 0.000 description 1
- WRYJYFCCMSVEPQ-MNIDVGFKSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,4r,4ar,6ar,6bs,8s,8as,14ar,14bs)-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,14a-dodecahydropicen-3-yl]oxy]-3,5-dihydroxy-6-methyloxan-4-yl]oxy-6-(hydroxymethyl)oxane Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@H](O)[C@@]6(CO)CCC(C)(C)CC6=C5C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WRYJYFCCMSVEPQ-MNIDVGFKSA-N 0.000 description 1
- QBLFZIBJXUQVRF-UHFFFAOYSA-N (4-bromophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Br)C=C1 QBLFZIBJXUQVRF-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 1
- 108091005477 5-HT3 receptors Proteins 0.000 description 1
- 102000017462 5-hydroxytryptamine 3 receptors Human genes 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 241000605445 Anemarrhena asphodeloides Species 0.000 description 1
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- RRTBTJPVUGMUNR-UHFFFAOYSA-N Cycloartanol Natural products C12CCC(C(C(O)CC3)(C)C)C3C2(CC)CCC2(C)C1(C)CCC2C(C)CCCC(C)C RRTBTJPVUGMUNR-UHFFFAOYSA-N 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- QWCNQXNAFCBLLV-IAGOWNOFSA-N Falcarindiol Natural products CCCCCCCC=C/[C@@H](O)C#CC#C[C@H](O)C=C QWCNQXNAFCBLLV-IAGOWNOFSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 102000003710 Histamine H2 Receptors Human genes 0.000 description 1
- 108090000050 Histamine H2 Receptors Proteins 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- QURCVMIEKCOAJU-HWKANZROSA-N Isoferulic acid Natural products COC1=CC=C(\C=C\C(O)=O)C=C1O QURCVMIEKCOAJU-HWKANZROSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- KYWSCMDFVARMPN-MSSMMRRTSA-N Saikosaponin A Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-MSSMMRRTSA-N 0.000 description 1
- WRYJYFCCMSVEPQ-ORAXXRKOSA-N Saikosaponin b2 Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@@]6(CO)CCC(C)(C)CC6=C5C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WRYJYFCCMSVEPQ-ORAXXRKOSA-N 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- 229940104299 cimicifugae rhizoma Drugs 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- YNBJLDSWFGUFRT-UHFFFAOYSA-N cycloartenol Natural products CC(CCC=C(C)C)C1CCC2(C)C1(C)CCC34CC35CCC(O)C(C)(C)C5CCC24C YNBJLDSWFGUFRT-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- QWCNQXNAFCBLLV-YWALDVPYSA-N falcarindiol Chemical compound CCCCCCC\C=C/[C@H](O)C#CC#C[C@H](O)C=C QWCNQXNAFCBLLV-YWALDVPYSA-N 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 229930192014 saikosaponin Natural products 0.000 description 1
- WRYJYFCCMSVEPQ-IPNFWLSTSA-N saikosaponin b1 Natural products C[C@H]1O[C@@H](O[C@H]2CC[C@@]3(C)[C@@H](CC[C@]4(C)[C@@H]3C=CC5=C6CC(C)(C)CC[C@]6(CO)[C@@H](O)C[C@]45C)[C@]2(C)CO)[C@H](O)[C@@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H]1O WRYJYFCCMSVEPQ-IPNFWLSTSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000005127 stratified epithelium Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本申请公开了一种防治新型冠状病毒肺炎的中药组合物及其饮品的制备方法。其中所述中药组合物由以下原料按照质量比混合而成:生黄芪13‑17份、党参13‑17份、苍术3‑7份、升麻1‑5份、柴胡1‑5份、甘草3‑7份、鸡内金1‑5份、淡豆豉1‑5份、知母3‑7份、桑叶13‑17份、银花1‑5份、薄荷1‑5份、羌活3‑7份、荆芥3‑7份、紫苏3‑7份。本发明的一个技术效果在于,将本发明的中药组合物煎煮后的滤液作为饮品服用,能够用于新型冠状病毒肺炎的防治。
Description
技术领域
本申请属于中药研发领域,具体地说,涉及一种防治新型冠状病毒肺炎的中药组合物及其饮品的制备方法。
背景技术
基于流行病学调查发现,COVID-19潜伏期1~14天,多为3~7天,感染者以发热、乏力、干咳为主要表现,少数患者伴有鼻塞、流涕、咽痛和腹泻等症状。重症患者多在发病1周后出现呼吸困难和(或)低氧血症,严重者快速进展为急性呼吸窘迫综合征、脓毒症休克、难以纠正的代谢性酸中毒、凝血功能障碍等,值得注意的是重型、危重型患者病程中可表现为中低热,甚至无明显发热。轻型患者仅表现为低热、轻微乏力等,无肺炎表现。目前西医药在防治COVID-19尚无针对 SARS-COV-2病毒的疫苗及确认有效的治疗药物,临床仍以对症治疗、改善症状为主。因此,有必要提供一种用于防治新型冠状病毒肺炎的中药组合物。
发明内容
本发明的一个目的是提供一种防治新型冠状病毒肺炎的中药组合物的技术方案。
根据本发明的一个方面,本发明提供一种防治新型冠状病毒肺炎的中药组合物,由以下原料按照质量比混合而成:生黄芪13-17份、党参13-17份、苍术3-7份、升麻1-5份、柴胡1-5份、甘草3-7份、鸡内金1-5份、淡豆豉 1-5份、知母3-7份、桑叶13-17份、银花1-5份、薄荷1-5份、羌活3-7份、荆芥3-7份、紫苏3-7份。
可选地,由以下原料按照质量比混合而成:生黄芪15份、党参15份、苍术5份、升麻3份、柴胡3份、甘草5份、鸡内金3份、淡豆豉3份、知母5份、桑叶15份、银花3份、薄荷3份、羌活5份、荆芥5份、紫苏5 份。
根据本发明的另一个方面,本发明还提供一种防治新型冠状病毒肺炎饮品的制备方法,包括以下步骤:
提供上述的中药组合物;
加水,将所述中药组合物浸泡得到混合物;
煎煮,将所述混合物煮沸后煎煮;
过滤,对煎煮后的所述混合物进行过滤分离,得到滤液;
浓缩,对所述滤液进行浓缩,得到所述防治新型冠状病毒肺炎饮品。
可选地,包括以下步骤:
对所述混合物进行第一次煎煮,过滤后得到第一药渣和第一滤液;
对所述第一药渣加水后进行第二次煎煮,过滤后得到第二药渣和第二滤液;
将所述第一滤液和所述第二滤液合并浓缩。
可选地,所述第一次煎煮时间为煮沸后煎煮20-40分钟;所述第二次煎煮时间为煮沸后煎煮20-40分钟。
可选地,所述第一次煎煮时间为煮沸后煎煮30分钟;所述第二次煎煮时间为煮沸后煎煮30分钟。
可选地,所述中药组合物由以下原料按照质量比混合而成:生黄芪15g、党参15g、苍术5g、升麻3g、柴胡3g、甘草5g、鸡内金3g、淡豆豉3g、知母5g、桑叶15g、银花3g、薄荷3g、羌活5g、荆芥5g、紫苏5g,所述滤液浓缩至10-20ml。
可选地,所述滤液浓缩至15ml。
可选地,所述中药组合物加水浸泡20-40分钟得到所述混合物。
可选地,所述中药组合物加水浸泡30分钟得到所述混合物。
本发明的一个技术效果在于,将本发明的中药组合物煎煮后的滤液作为饮品服用,能够用于新型冠状病毒肺炎的防治。
具体实施方式
以下将配合实施例来详细说明本申请的实施方式,借此对本申请如何应用技术手段来解决技术问题并达成技术功效的实现过程能充分理解并据以实施。
本发明提供一种防治新型冠状病毒肺炎的中药组合物。
实施例1,由以下原料按照质量比混合而成:生黄芪13份、党参13 份、苍术3份、升麻1份、柴胡1份、甘草3份、鸡内金1份、淡豆豉1 份、知母3份、桑叶13份、银花1份、薄荷1份、羌活3份、荆芥3份、紫苏3份。
实施例2,由以下原料按照质量比混合而成:生黄芪17份、党参17 份、苍术7份、升麻5份、柴胡5份、甘草7份、鸡内金5份、淡豆豉5 份、知母7份、桑叶17份、银花5份、薄荷5份、羌活7份、荆芥7份、紫苏7份。
实施例3,由以下原料按照质量比混合而成:生黄芪15份、党参15 份、苍术5份、升麻3份、柴胡3份、甘草5份、鸡内金3份、淡豆豉3 份、知母5份、桑叶15份、银花3份、薄荷3份、羌活5份、荆芥5份、紫苏5份。
将本发明的中药组合物煎煮后的滤液作为饮品服用,能够用于新型冠状病毒肺炎的防治。
本发明技术方案中黄芪、党参、甘草入脾、肺经,甘平益气健脾,脾胃健则元气充足,而百病得止,更寓培土生金,以救肺金,恢复肺之治节,而宣发肃降有常;柴胡、升麻配黄芪引胃中清气上行,即″举清阳则阴气自降″,寓降于升之中,清气上行则浊阴自降,故嗔胀、飧泻自止。升麻为足阳明、太阴引经之药,使行阳道,以行少阳行春令;配柴胡,生发阴阳之气,以达木郁;羌活为风药,借风药之力上行,能散能升,助升、柴升发清阳,则″清阳发腠理,浊阴走五脏″,脾气得以散精,灌溉四旁,布散于脏腑及肢体皮毛,此乃″正气存内,邪不可干″;苍术温燥,醒脾芳香化寒浊,羌活配以借东风之力胜湿;荆芥、苏叶辛温,配羌活以解表散寒,开太阳枢机,三者合有用入拨云见日,更利寒湿宣散,且苏叶温中下气,可治腹胀、呕逆;虽木郁解,湿邪去,而上炎之标热仍需亟除,佐以薄荷、淡豆豉辛凉,轻轻宣散,即为火郁发之,且薄荷可通鼻窍、清头目,更解肝郁,淡豆豉除胸中之烦闷。肺为娇脏,上炎之火刑金,则肺金焦燥,故以桑叶、银花清热救肺,且肺润恶燥,配知母以润之,更制辛温之药燥热伤津。佐鸡内金以化滞开胃,更暗寓酉鸡为金,以坚肺脏。诸药合用,元气充足,阳气升发,则阴霾自行消散,阴阳各归其位,阴气恢复潜藏之职,阴火随之消退。本发明技术方案灵活审慎,调理脏腑,主次分明,分合有道,具有防治新型冠状病毒感染肺炎,调和阴阳气血、恢复脏腑神机、通利官窍肢节的作用。本发明技术方案对新型冠状病毒肺炎的预防及普通流感预防具有确切作用;对于新型冠状病毒肺炎普通型患者,可改善症状,缩短病程;对于新型冠状病毒肺炎重症、危重症患者,能防止病情恶化;对于恢复期患者,可促进康复进程。
黄芪中发挥药理作用的主要成分是多糖及皂甙类,以及黄酮类,多种氨基酸,微量元素,甾醇类及挥发成分,可调节生物免疫系统,影响多种免疫细胞活性,细胞因子产生和分泌,抗体生成等,具有显著提高免疫力,抑制自由基产生,延长细胞寿命,抗机体衰老的作用。
党参以糖甙类为主要成分,除此之外还含多种氨基酸、微量元素、甾体类、生物碱类,挥发成分、三萜类等,可能通过抑制炎症反应、降低脂质氧化、抑制细胞凋亡等途径发挥药理作用。党参多糖能明显增强实验动物的细胞免疫,主要是增加巨噬细胞数量,吞噬能力。除此之外,党参可改善肺呼吸功能,减轻低氧血症,改善肺泡吞噬细胞能力缺陷和降低血浆IL-6、 IL-8、TNF-α水平,可能与改善肺泡细胞相关物质结构和功能以及降低炎症反应有关。黄芪、党参配伍使用,两药合用能提高超氧化物歧化酶,降低丙二醛活性,起到抗氧化的作用;同时可改善实验动物纳差、腹泻、精神不振、皮毛暗黄、胃肠蠕动亢进等症状,提高IL-2、干扰素、自然杀伤细胞免疫调节水平,具有免疫增强、免疫调节及耐疲劳的作用。除此之外,两药合用还能协同增强小肠推进率和增加大肠水分含量,改善胃肠道平滑肌应激状态、调节基本电节律紊乱,明显拮抗5-HT引起的回肠收缩。
苍术及其活性成分具有抗微生物作用,常被制成香囊用于空气消毒防流感;水煎剂具有抗炎、免疫调节作用以及具有多巴胺D2受体、5-羟色胺-3- 受体和组织胺H2受体的阻断作用,具有促进胃排空、调节胃肠推进运动、抗腹泻、保肝和提高消化吸收功能作用。
甘草含有甘草总黄酮、甘草酸、甘草次酸、三萜类、甘草苷等成分,有抗氧化、抗炎、调免疫、抗病毒等作用。
柴胡主要成分为柴胡皂苷,其次含有植物甾醇,侧金盏花醇,以及少量挥发油、多糖。大剂量柴胡煎剂有解热作用,其有效成分为柴胡挥发油;柴胡抗炎的有效成分为柴胡皂苷,柴胡皂苷对许多炎症过程包括渗出、毛细血管通透性、炎性介质释放、白细胞游走和结缔组织增生等都有影响。柴胡中的有效成分柴胡皂苷a、d和二次生成的柴胡皂苷b1、b2、b3、b4对于Na+-K+ -ATP酶有很强的抑制作用,能引起能量和水盐代谢的变化从而起到抗病毒作用。
羌活中含有的镰叶芹二醇具有明显的抑菌作用,可抑制金黄色葡萄球菌的生长;能通过抑制NO分泌表现出抗炎活性。羌活中含有的乙酸乙酯具有镇痛作用,其挥发油、多糖等成分具有抗氧化活性,在一定范围内随质量浓度升高呈线性增大,这可能与其能激活Nrf2/ARE信号通路、清除DPPH或 OH自由基、抑制5-脂氧合酶、环加氧酶等作用有关。
升麻主要含有环阿尔廷烷型三萜皂苷和肉桂酸衍生物两大类化合物,另外还有一些色原酮类和含氮化合物,具有抗炎、解热镇痛、解痉、抗氧化等多种生理活性。所含的异阿魏酸和阿魏酸可以降低流感病毒侵染小鼠支气管肺泡灌洗液中的IL-8的水平,升麻甲醇提取物的水溶部分可使大鼠正常体温下降。
知母具有抗血小板血栓、抗炎、解热等作用。知母可明显减轻长期口服糖皮质激素产生的副作用。
桑叶、银花具有抗炎、抗氧化、抗肿瘤、降血糖、抗高血脂、保肝等作用。
薄荷有效成分为挥发油,有祛痰、抗炎镇痛作用、促进透皮吸收作用、抗真菌、抗病毒作用,也具有保护急性肝损、利胆、抑制回肠活动、对抗肠管活动亢进的作用。
荆芥挥发油及荆芥醇提取物具有一定的抗流感病毒作用,能够明显抑制病菌孢子生长,具有良好的抗菌作用,能够降低IL-6、TNF-α的同时升高IFN- α、IFN-β、IL-2含量,从而达到体内抗病毒感染作用。荆芥与金银花等共同配伍时能够增强机体抗菌作用,且与西药联合应用时明显降低药物毒性。
淡豆豉对呼吸道致病菌及其他常见致病菌均显示较强的抗菌活性,对人体6种肠道常住菌具有不同程度的调节作用。
鸡内金具有抗氧化、改善血糖血脂水平和血液流变学参数以及改善肠胃功能等作用,鸡内金具有增加小肠推进率的作用。
最新研究表明,2019-nCoV病毒通过细胞受体ACE2进入宿主细胞。在人体中,ACE2不仅在肺细胞表达、食道上皮和复层上皮细胞中高表达,而且在回肠和结肠的吸收性肠上皮细胞中也高表达。专家通过对单细胞转录组的生物信息学分析,认为消化道可能是2019-nCov潜在感染的途径。由此可见,2019-nCoV病毒作用部位与感染患者所表现出来的呼吸道症状、消化道症状相符。通过对既往药理学研究文献的分析,本发明技术方案的药物组成具有提高机体免疫力、抗病毒、抗炎、抗疲劳,改善肺呼吸功能、提高氧代谢,促进胃肠道蠕动、调节基本电节律紊乱的功效。
根据本发明的另一个方面,本发明还提供一种防治新型冠状病毒肺炎饮品的制备方法,在一些实施例中,包括以下步骤:
提供上述的中药组合物;
加水,将所述中药组合物浸泡得到混合物;
煎煮,将所述混合物煮沸后煎煮;
过滤,对煎煮后的所述混合物进行过滤分离,得到滤液;
浓缩,对所述滤液进行浓缩,得到所述防治新型冠状病毒肺炎饮品。
进一步的,对所述混合物煎煮两次,过滤两次,即对所述混合物进行第一次煎煮,过滤后得到第一药渣和第一滤液,对所述第一药渣加水后进行第二次煎煮,过滤后得到第二药渣和第二滤液,将所述第一滤液和所述第二滤液合并浓缩;以增加有效成分的提取量。
进一步的,所述第一次煎煮时间为煮沸后煎煮20-40分钟;所述第二次煎煮时间为煮沸后煎煮20-40分钟。优选的是,所述第一次煎煮时间为煮沸后煎煮30分钟;所述第二次煎煮时间为煮沸后煎煮30分钟。
进一步的,由以下原料按照质量比混合而成:生黄芪15g、党参15g、苍术5g、升麻3g、柴胡3g、甘草5g、鸡内金3g、淡豆豉3g、知母5g、桑叶15g、银花3g、薄荷3g、羌活5g、荆芥5g、紫苏5g的中药组合物制得的所述滤液浓缩至10-20ml。优选的,所述滤液浓缩至15ml。
进一步的,所述中药组合物加水浸泡20-40分钟得到所述混合物。优选的,所述中药组合物加水浸泡30分钟得到所述混合物。
实施例4,防治新型冠状病毒肺炎饮品的制备,包括以下步骤:
提供中药组合物由以下原料按照质量比混合而成:生黄芪15g、党参15g、苍术5g、升麻3g、柴胡3g、甘草5g、鸡内金3g、淡豆豉3g、知母5g、桑叶15g、银花3g、薄荷3g、羌活5g、荆芥5g、紫苏5g;
向所述中药组合物加水混合得到混合物,浸泡30分钟;
进行第一次煎煮,煮沸后继续煎煮30分钟,过滤后得到第一药渣和第一滤液;
对所述第一药渣加水后进行第二次煎煮,煮沸后继续煎煮30分钟,过滤后得到第二药渣和第二滤液;
将所述第一滤液和所述第二滤液合并浓缩至15ml;
为了方便携带,将浓缩后的滤液冷却封装,为1人份剂量。
2020年1月27日至2020年02月11日,向受试者供应实施例4制备得到的防治新型冠状病毒肺炎饮品22910人份,每人服用益气清瘟饮时间已有 3-14天不等。经随访及数据统计,在服用益气清瘟饮的普通群众和医学观察期人群中,未发生″新冠肺炎″疑似或确诊病例。服用前共有轻微呼吸道症状及消化道症状者276例,其中低热者11例,咽干、咽痛、干咳者243例,困倦乏力者35例,食欲不佳者49例,自觉燥热者18例。服用本药1-2周后,低热症状改善者81.8%,咽干、咽痛、干咳缓解者86.4%,困倦乏力缓解者80%,食欲改善者83.7%,自觉燥热改善者88.9%,总体症状明显缓解者91.5%。收到反馈服药后出现轻微腹泻18例,轻微胃胀11例,占服用人群0.141%,余无其他不适及副作用。此外,本发明受试者″新冠肺炎″重症患者2例,两位患者服用本方后分别以半剂和一剂热退,半日到一日时间内体温从38.5 ℃降至36.4℃,心率从发热时106次/分和98次/分,降至体温正常范围时的 66次/分,呼吸急促、气喘明显缓解,患者服药后食欲及睡眠改善,次日有纳食需要并可平静入睡,继用5剂后临床症状明显缓解。本方能明显改善医学观察期人群的临床症状,有预防2019-nCoV感染的优势,有减少重型肺炎发生的趋势,具有较好的临床应用价值。经本发明治疗确诊的″新冠肺炎″重症患者10例,本发明在病毒核酸转阴时间及全部流感症状缓解时间方面与磷酸奥司他韦无差异,退热及缓解咳嗽、肌肉酸痛、乏力等症状优于磷酸奥司他韦。
在临床实践过程中,变量仅为实施例4制备得到的防治新型冠状病毒肺炎饮品,进行中西医结合治疗,与西医组的临床治疗指标对比如表1中所示;
表1两组患者临床疗效指标比较
综上所述,本发明具有:1.标本兼治,突破西医治疗局限,传承传统中医中药在治疗疾病中的优势,在治疗疾病的同时,能调节各脏腑气血、阴阳,使机体处于平衡状态。具体体现在对于普通型患者,该发明可改善症状,缩短病程。对于重症、危重症患者,该发明通过减少肺的渗出、抑制炎性因子释放、稳定血氧饱和度、减少呼吸支持力度等,防止病情恶化。对于恢复期患者,该发明可通过清除余邪,扶助正气,改善患者症状,同时可促进肺部炎症的吸收,减少粘连,促进损伤脏器组织的彻底修复等促进康复进程;2. 中医治未病作用,从患者整体、体质状态出发,能有效发挥未病先防、疾病防变作用;3.从西医角度上,该发明可提高机体免疫力、抗病毒、抗炎、抗疲劳,改善肺呼吸功能、提高氧代谢,促进胃肠道蠕动、调节基本电节律紊乱。4.作用迅速,且副作用少,疗效显著。
如在说明书及权利要求当中使用了某些词汇来指称特定成分或方法。本领域技术人员应可理解,不同地区可能会用不同名词来称呼同一个成分。本说明书及权利要求并不以名称的差异来作为区分成分的方式。如在通篇说明书及权利要求当中所提及的“包含”为一开放式用语,故应解释成“包含但不限定于”。“大致”是指在可接收的误差范围内,本领域技术人员能够在一定误差范围内解决所述技术问题,基本达到所述技术效果。说明书后续描述为实施本申请的较佳实施方式,然所述描述乃以说明本申请的一般原则为目的,并非用以限定本申请的范围。本申请的保护范围当视所附权利要求所界定者为准。
还需要说明的是,术语“包括”、“包含”或者其任何其他变体意在涵盖非排他性的包含,从而使得包括一系列要素的商品或者系统不仅包括那些要素,而且还包括没有明确列出的其他要素,或者是还包括为这种商品或者系统所固有的要素。在没有更多限制的情况下,由语句“包括一个……”限定的要素,并不排除在包括所述要素的商品或者系统中还存在另外的相同要素。
上述说明示出并描述了发明的若干优选实施例,但如前所述,应当理解发明并非局限于本文所披露的形式,不应看作是对其他实施例的排除,而可用于各种其他组合、修改和环境,并能够在本文所述发明构想范围内,通过上述教导或相关领域的技术或知识进行改动。而本领域人员所进行的改动和变化不脱离发明的精神和范围,则都应在发明所附权利要求的保护范围内。
Claims (10)
1.一种防治新型冠状病毒肺炎的中药组合物,其特征在于,由以下原料按照质量比混合而成:生黄芪13-17份、党参13-17份、苍术3-7份、升麻1-5份、柴胡1-5份、甘草3-7份、鸡内金1-5份、淡豆豉1-5份、知母3-7份、桑叶13-17份、银花1-5份、薄荷1-5份、羌活3-7份、荆芥3-7份、紫苏3-7份。
2.根据权利要求1所述的中药组合物,其特征在于,由以下原料按照质量比混合而成:生黄芪15份、党参15份、苍术5份、升麻3份、柴胡3份、甘草5份、鸡内金3份、淡豆豉3份、知母5份、桑叶15份、银花3份、薄荷3份、羌活5份、荆芥5份、紫苏5份。
3.一种防治新型冠状病毒肺炎饮品的制备方法,其特征在于,包括以下步骤:
提供权利要求1或2所述的中药组合物;
加水,将所述中药组合物浸泡得到混合物;
煎煮,将所述混合物煮沸后煎煮;
过滤,对煎煮后的所述混合物进行过滤分离,得到滤液;
浓缩,对所述滤液进行浓缩,得到所述防治新型冠状病毒肺炎饮品。
4.根据权利要求3所述的制备方法,其特征在于,包括以下步骤:
对所述混合物进行第一次煎煮,过滤后得到第一药渣和第一滤液;
对所述第一药渣加水后进行第二次煎煮,过滤后得到第二药渣和第二滤液;
将所述第一滤液和所述第二滤液合并浓缩。
5.根据权利要求4所述的制备方法,其特征在于,所述第一次煎煮时间为煮沸后煎煮20-40分钟;所述第二次煎煮时间为煮沸后煎煮20-40分钟。
6.根据权利要求5所述的制备方法,其特征在于,所述第一次煎煮时间为煮沸后煎煮30分钟;所述第二次煎煮时间为煮沸后煎煮30分钟。
7.根据权利要求3或4所述的制备方法,其特征在于,所述中药组合物由以下原料按照质量比混合而成:生黄芪15g、党参15g、苍术5g、升麻3g、柴胡3g、甘草5g、鸡内金3g、淡豆豉3g、知母5g、桑叶15g、银花3g、薄荷3g、羌活5g、荆芥5g、紫苏5g,所述滤液浓缩至10-20ml。
8.根据权利要求7所述的制备方法,其特征在于,所述滤液浓缩至15ml。
9.根据权利要求3所述的制备方法,其特征在于,所述中药组合物加水浸泡20-40分钟得到所述混合物。
10.根据权利要求3所述的制备方法,其特征在于,所述中药组合物加水浸泡30分钟得到所述混合物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010395720.8A CN111920897A (zh) | 2020-05-12 | 2020-05-12 | 一种防治新型冠状病毒肺炎的中药组合物及其饮品的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010395720.8A CN111920897A (zh) | 2020-05-12 | 2020-05-12 | 一种防治新型冠状病毒肺炎的中药组合物及其饮品的制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111920897A true CN111920897A (zh) | 2020-11-13 |
Family
ID=73317536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010395720.8A Pending CN111920897A (zh) | 2020-05-12 | 2020-05-12 | 一种防治新型冠状病毒肺炎的中药组合物及其饮品的制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111920897A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102397329A (zh) * | 2011-11-12 | 2012-04-04 | 句文宝 | 一种用于治疗肠胃型感冒的药物 |
| CN105055606A (zh) * | 2015-09-25 | 2015-11-18 | 刘瑞云 | 一种治疗感冒的药物 |
| CN112220123A (zh) * | 2020-04-28 | 2021-01-15 | 谢胜 | 一种中药保健口罩 |
-
2020
- 2020-05-12 CN CN202010395720.8A patent/CN111920897A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102397329A (zh) * | 2011-11-12 | 2012-04-04 | 句文宝 | 一种用于治疗肠胃型感冒的药物 |
| CN105055606A (zh) * | 2015-09-25 | 2015-11-18 | 刘瑞云 | 一种治疗感冒的药物 |
| CN112220123A (zh) * | 2020-04-28 | 2021-01-15 | 谢胜 | 一种中药保健口罩 |
Non-Patent Citations (1)
| Title |
|---|
| 任寿山: "感冒辨治举隅", 《中国临床医生》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105412858A (zh) | 一种糖浆及其制备方法 | |
| CN104324125B (zh) | 一种治疗慢性咽炎的中药组合物及其制备方法 | |
| CN110237174A (zh) | 一种治疗感冒咳嗽的燥湿中药组合物及其制备方法 | |
| CN108210657A (zh) | 一种预防和治疗肺癌的中药组合物 | |
| CN101987135B (zh) | 一种治疗破伤风的药物及其制备方法 | |
| CN110652552A (zh) | 一种伤口愈合配方及制备方法 | |
| CN104435535A (zh) | 一种治疗ⅱ型糖尿病的保健药品 | |
| CN111920897A (zh) | 一种防治新型冠状病毒肺炎的中药组合物及其饮品的制备方法 | |
| CN102793868B (zh) | 一种治疗喘促型闭合性骨折的中药洗剂制备方法 | |
| CN107823293A (zh) | 治疗口腔溃疡的瑶医外用散剂及其制备方法 | |
| KR100712659B1 (ko) | 당뇨병 및 이로 인한 합병증 치료 및 예방용 한약조성물 | |
| CN104353043A (zh) | 一种治疗五更泻的中药组合物及其制备方法 | |
| CN1879788A (zh) | 病毒清胶囊 | |
| CN104258224A (zh) | 一种治疗肺肾阴虚型慢性支气管炎的五味子口服液及其制备方法 | |
| CN108452213A (zh) | 一种治疗鼻炎的中药组合物、中药制剂及其制备方法 | |
| CN120550026A (zh) | 一种中药组合物及其应用 | |
| CN118924868A (zh) | 一种治疗咳嗽的中药外敷组合物 | |
| CN119386123A (zh) | 一种用于治疗过敏性鼻炎的口服组合物 | |
| CN105412643A (zh) | 一种治疗小儿水气凌心型哮喘的喷雾剂及其制备方法 | |
| CN105250417A (zh) | 一种治疗腹泻型肠易激综合征的药物组合物及其应用 | |
| CN119097678A (zh) | 一种治疗小儿鼾症的中药组合物及其应用 | |
| CN118948915A (zh) | 中药组合物及汤剂制备方法 | |
| CN113662980A (zh) | 一种保健足浴组合物 | |
| CN104042924A (zh) | 一种治疗气血亏虚型骨性关节炎的中药制剂及其制备方法 | |
| CN104906352A (zh) | 一种治疗虚火上炎型小儿口疮的中药药液及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201113 |
|
| RJ01 | Rejection of invention patent application after publication |
